Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

Kiplinger

Health Care Giant McKesson Dives Amid Big Revenue Miss

McKesson earnings beat estimates, but the drug and health supplies distribution giant badly missed sales estimates.

Investors Business Daily

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

PetIQ Stock Rockets 48% To A Three-Year High On A $1.5 Billion Takeover

Pet medications wholesaler PetIQ agreed to a $1.5 billion buyout Wednesday, sending shares into the stratosphere.

Investors Business Daily

How These Two Lesser-Known Biotech Names Obliterated Sales Expectations

Halozyme Therapeutics obliterated second-quarter expectations, and the No. 1 biotech stock jumped early Wednesday.

Investors Business Daily

TG Therapeutics Stock Rockets As Surprise Profit Smashes Views By 157%

TG Therapeutics stock popped Tuesday after the drugmaker unexpectedly reported a second-quarter profit, thanks to significantly lower R&D.

Investors Business Daily

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.

Moderna stock, which lost 27% of its value over two days, tumbled again Monday on a rare downgrade amid uncertainty for its vaccines.

Investors Business Daily

Drugstores tinker with new looks as their usual way of doing business faces challenges

America’s drugstores are testing smaller locations and more ways to offer care as more store closings loom

The Independent UK

Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat

Moderna cut its outlook early Thursday despite delivering nearly double strong quarterly sales. Moderna stock tumbled.

Investors Business Daily

GSK’s health is improving. Shame about the legal heartburn

Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed

The Guardian - UK

Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Kiplinger

Reckitt Benckiser’s shares slump after Abbott baby formula ruling over bowel disease link

British group says claims products cause serious bowel condition NEC are ‘not supported by science’

The Guardian - UK

NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations

NewAmsterdam said Monday its experimental drug lowered "bad" LDL cholesterol But the results were below biotech stock analysts' views.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.

AAP

'Grinding halt': shortage could cause hospital chaos

Australia's health system could come to a "grinding halt" within days if a shortage of intravenous fluid isn't addressed, a leading doctor has warned.

Investors Business Daily

Medical Giant Danaher Nears Breakout On This 'Stark Contrast' With A Key Rival

Danaher stock flirted with a breakout Tuesday on the back of its unexpectedly strong sales from its molecular testing services.

International Business Times

Bosses Resign At Japan Health Supplement Firm Probing Deaths

The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes dozens of deaths potentially linked to products meant to lower cholesterol.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The 'Shocking' And 'Alarming' Report That Sent IBD 50's Medpace Into A Nosedive

Medpace stock crumbled late Tuesday on a "shocking bookings miss" and after slashing its 2024 sales guidance by $25 million at the midpoint.

The Conversation

Dear Pharmac – do things differently: what David Seymour’s expectations could mean for the drug-buying agency

Associate Health Minister David Seymour’s recent letter of expectations to drug buying agency Pharmac could fundamentally change the way the organisation makes decisions. Some of these changes could also make Pharmac’s job harder and its decisions more unpopular.

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

Investors Business Daily

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.

Investors Business Daily

Iqvia Bolts Higher After A Surprise Segment Beat Saved Its Second Quarter

Iqvia stock bolted higher Monday after the contract research firm raised its outlook for the year on the back of unexpected strength.

International Business Times

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

StockNews.com

3 Healthcare Stocks With High Profit Margins

With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.